Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?

FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.